TCNNF
Price
$7.51
Change
-$0.60 (-7.40%)
Updated
Aug 15 closing price
Capitalization
1.45B
81 days until earnings call
TSMRF
Price
$23.74
Change
-$4.41 (-15.67%)
Updated
Jun 27 closing price
Capitalization
1.8B
Interact to see
Advertisement

TCNNF vs TSMRF

Header iconTCNNF vs TSMRF Comparison
Open Charts TCNNF vs TSMRFBanner chart's image
Trulieve Cannabis
Price$7.51
Change-$0.60 (-7.40%)
Volume$1.6M
Capitalization1.45B
Tsumura & Co
Price$23.74
Change-$4.41 (-15.67%)
Volume$100
Capitalization1.8B
TCNNF vs TSMRF Comparison Chart in %
Loading...
TCNNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSMRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TCNNF vs. TSMRF commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TCNNF is a Hold and TSMRF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (TCNNF: $7.51 vs. TSMRF: $23.74)
Brand notoriety: TCNNF and TSMRF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TCNNF: 230% vs. TSMRF: 100%
Market capitalization -- TCNNF: $1.45B vs. TSMRF: $1.8B
TCNNF [@Pharmaceuticals: Generic] is valued at $1.45B. TSMRF’s [@Pharmaceuticals: Generic] market capitalization is $1.8B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TCNNF’s FA Score shows that 1 FA rating(s) are green whileTSMRF’s FA Score has 2 green FA rating(s).

  • TCNNF’s FA Score: 1 green, 4 red.
  • TSMRF’s FA Score: 2 green, 3 red.
According to our system of comparison, both TCNNF and TSMRF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TCNNF’s TA Score shows that 4 TA indicator(s) are bullish while TSMRF’s TA Score has 2 bullish TA indicator(s).

  • TCNNF’s TA Score: 4 bullish, 4 bearish.
  • TSMRF’s TA Score: 2 bullish, 1 bearish.
According to our system of comparison, TSMRF is a better buy in the short-term than TCNNF.

Price Growth

TCNNF (@Pharmaceuticals: Generic) experienced а +31.06% price change this week, while TSMRF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Reported Earning Dates

TCNNF is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TSMRF($1.8B) has a higher market cap than TCNNF($1.45B). TCNNF YTD gains are higher at: 44.883 vs. TSMRF (-15.672). TSMRF has higher annual earnings (EBITDA): 47.8B vs. TCNNF (275M). TSMRF has more cash in the bank: 82.4B vs. TCNNF (328M). TCNNF has less debt than TSMRF: TCNNF (824M) vs TSMRF (71.4B). TSMRF has higher revenues than TCNNF: TSMRF (165B) vs TCNNF (1.19B).
TCNNFTSMRFTCNNF / TSMRF
Capitalization1.45B1.8B80%
EBITDA275M47.8B1%
Gain YTD44.883-15.672-286%
P/E RatioN/A8.18-
Revenue1.19B165B1%
Total Cash328M82.4B0%
Total Debt824M71.4B1%
FUNDAMENTALS RATINGS
TCNNF vs TSMRF: Fundamental Ratings
TCNNF
TSMRF
OUTLOOK RATING
1..100
1642
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9331
PRICE GROWTH RATING
1..100
3578
P/E GROWTH RATING
1..100
1690
SEASONALITY SCORE
1..100
530

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TSMRF's Valuation (7) in the null industry is significantly better than the same rating for TCNNF (84). This means that TSMRF’s stock grew significantly faster than TCNNF’s over the last 12 months.

TSMRF's Profit vs Risk Rating (100) in the null industry is in the same range as TCNNF (100). This means that TSMRF’s stock grew similarly to TCNNF’s over the last 12 months.

TSMRF's SMR Rating (31) in the null industry is somewhat better than the same rating for TCNNF (93). This means that TSMRF’s stock grew somewhat faster than TCNNF’s over the last 12 months.

TCNNF's Price Growth Rating (35) in the null industry is somewhat better than the same rating for TSMRF (78). This means that TCNNF’s stock grew somewhat faster than TSMRF’s over the last 12 months.

TCNNF's P/E Growth Rating (16) in the null industry is significantly better than the same rating for TSMRF (90). This means that TCNNF’s stock grew significantly faster than TSMRF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TCNNFTSMRF
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
N/A
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 4 days ago
10%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
17%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
13%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
12%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
12%
View a ticker or compare two or three
Interact to see
Advertisement
TCNNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSMRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JICAX83.01N/A
N/A
JPMorgan US Sustainable Leaders A
PRCGX24.91N/A
N/A
Perritt MicroCap Opportunities Investor
WVAIX54.18N/A
N/A
Weitz Large Cap Equity-Institutional Cl
FCPAX35.23N/A
N/A
Fidelity Advisor Intl Capl App A
QAACX51.09N/A
N/A
Federated Hermes MDT All Cap Core A

TCNNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, TCNNF has been closely correlated with GTBIF. These tickers have moved in lockstep 83% of the time. This A.I.-generated data suggests there is a high statistical probability that if TCNNF jumps, then GTBIF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCNNF
1D Price
Change %
TCNNF100%
-7.35%
GTBIF - TCNNF
83%
Closely correlated
-12.40%
CURLF - TCNNF
80%
Closely correlated
-9.48%
VRNOF - TCNNF
76%
Closely correlated
-19.33%
TSNDF - TCNNF
76%
Closely correlated
+1.10%
CRLBF - TCNNF
75%
Closely correlated
-1.25%
More

TSMRF and

Correlation & Price change

A.I.dvisor tells us that TSMRF and INNPF have been poorly correlated (+-0% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TSMRF and INNPF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TSMRF
1D Price
Change %
TSMRF100%
N/A
INNPF - TSMRF
-0%
Poorly correlated
-99.14%
TKPHF - TSMRF
-0%
Poorly correlated
N/A
TCNNF - TSMRF
-1%
Poorly correlated
-7.35%
TEVJF - TSMRF
-1%
Poorly correlated
N/A
VEXTF - TSMRF
-4%
Poorly correlated
+2.72%
More